Renhuang Pharmaceuticals Rated ‘Outperform’ Target Price $7.00 by Beacon Equity ResearchDALLAS–Renhuang Pharmaceuticals (OTCBB: RHGP) has been rated Outperform with a price target of $7.00 by Beacon Equity Research Analyst, Lisa Springer, CFA.
The full report is available at http://www.BeaconEquityResearch.com.
Anyone interested in receiving alerts regarding Renhuang Pharmaceuticals research should email members@beaconequityresearch.com with “RHGP” in the subject line.
In the report, the analyst writes, “Renhuang Pharmaceuticals Inc. (RHGP) is a vertically integrated developer, manufacturer and distributor of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products in mainland China. It offers three major product lines: Acanthopanax-based natural medicinal products, the Shark Power healthcare series and Traditional Chinese Medicines, which currently represent 50%, 20% and 30% of sales, respectively.
“Renhuang has established a multi-channel research and development infrastructure in China consisting of some 50 in-house researchers and engineers, a post-doctoral work center approved and supported by the Chinese government, and collaborations with leading institutions and scientists.”
About Renhuang Pharmaceuticals, Inc.
Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP) was founded in 1996 in Harbin, Heilongjiang province in Northeast China. In September 2006, the Company became a public company in the United States through a reverse merger and is currently traded on OTCBB (RHGP.OB).
Renhuang Pharmaceuticals is an integrated developer, manufacturer and distributor of a broad line of high-quality nutraceutical, biopharmaceutical, and natural medicinal products. The Company provides three major product lines including the Acanthopanax-based natural medicinal products, biopharmaceutical products, and Traditional Chinese Medicines, currently representing roughly 50%, 20%, and 30% of total revenues, respectively. Renhuang’s key product line is an Acanthopanax-based product series, a natural medicine effective in treating depression and melancholy, and provides numerous other health benefits. By controlling an estimated 70% of China’s natural resource of Acanthopanax (also known as Siberian Ginseng), the Company possesses a unique competitive edge and, therefore, occupies a dominant market position in Acanthopanax-based medicinal and nutraceutical products.
Renhuang distributes its products through a multi-layered sales network of over 2,000 sales agents organized under 70 sales centers across 24 districts that cover over 50% of greater China. Its products are not only sold nationwide but also exported to Russia and Southeast Asia.
The Company has established a multi-channel research and development infrastructure composed of in-house researchers, a government approved post-doctoral working center and collaborations with well-known institutions and scientists. The Company has achieved significant progress in research and development of standard extraction, separation of effective components, and medication with specificity.
Renhuang has three manufacturing facilities producing over 200 types of nutraceutical and medicinal products in various forms. The Company strictly follows the international GMP certified quality processes and systems by utilizing cutting-edge technologies, state-of-the-art equipment, and proprietary innovative and award winning processes.
As a fast-growing pharmaceutical company, Renhuang has been working hard to achieve operational excellence and to create value for their shareholders. At Renhuang, they value efficiency, innovation, and integrity. They strive to advance the science and technology of the pharmaceutical industry for the greater benefit of humankind, while putting their consumers first. They aspire to share their knowledge of Chinese Traditional Medicine with people around the world. Renhuang is dedicated to the development of the pharmaceutical industry in China in the 21st century. Their goal is to become a national leader in the biopharmaceutical industry in China in developing, manufacturing, and distributing high-quality, innovative nutraceutical, natural medicinal and biopharmaceutical products.
Their Mission
To become a national leader in the biopharmaceutical industry in China in developing, manufacturing, and distributing high-quality, innovative nutraceutical, natural medicinal, and biopharmaceutical products.
Corporate Spirit
To be an uplifting entrepreneur, always reaching higher.
Core Values
Create value with passion, responsibility, loyalty, and innovation.
Business Philosophy
To serve their consumers with credibility, trust, and respect.
Management Philosophy
Focus on results but execute on details.
Hiring Philosophy
They hire those people who want to do, can do, and have done.
vSafety Slogan
Life is in my hands and safety is on my mind.
Investment Highlights
– Leading Chinese pharmaceutical company providing high quality nutraceutical, natural medicinal, and bio-pharmaceutical products
– Vertically integrated manufacturer
– High growth in sales and income driven by rapid growth of consumption demand in China
– High value-added product portfolio
– Dominant market player in Acanthopanax based products by controlling estimated 70% of China’s natural supply
– Market leader in traditional over-the-counter medical products
– International GMP certified manufacturing facilities
– Multi-channel R&D infrastructure
– Large multi-layer distribution network
– Advanced information management system for internal control
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure:Disclosure: Pentony Enterprises LLC expects to be compensated as much at $12,300 for profile coverage from StockPromoters.com. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
